Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice

Lindsay S Hall, Charlotte S Lennon, Andrew M Hall, Stanislaw J. Urbaniak, Mark A Vickers, Robert N Barker (Corresponding Author)

Research output: Contribution to journalArticle

4 Downloads (Pure)

Abstract

Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. None of the individual peptides, delivered by a putative tolerogenic regimen, consistently suppressed the antibody response to subsequent immunization with human platelet glycoprotein IIb/IIIa. However, the combination of GPIIIa peptides aa6-20 and aa711-725, which contain the predominant helper epitopes in patients and elicited the strongest trends to suppress when used individually, did abrogate this response. The peptide combination also blunted, but did not reverse, the ongoing antibody response when given after immunization. Suppression of antibody was associated with reduced splenocyte T cell responsiveness to the antigen, and with the induction of a regulatory T cell population that is more responsive to the peptides than to purified platelet glycoprotein IIb/IIIa. Overall, these data demonstrate that combinations of peptides containing helper epitopes, such as platelet glycoprotein IIIa aa6-20 and aa711-725, can promote in vivo suppression of responses to the major antigen implicated in immune thrombocytopenia. The approach offers a promising therapeutic option to boost T cell regulation, which should be taken forward to clinical trials.
Original languageEnglish
Pages (from-to)1074-1082
Number of pages9
JournalHaematologica
Volume104
Issue number5
Early online date4 Dec 2018
DOIs
Publication statusPublished - May 2019

Fingerprint

Integrin beta3
Autoantigens
Helper-Inducer T-Lymphocytes
Immunotherapy
Transgenic Mice
Blood Platelets
Peptides
Platelet Glycoprotein GPIIb-IIIa Complex
Idiopathic Thrombocytopenic Purpura
Antibodies
Epitopes
Regulatory T-Lymphocytes
T-Lymphocytes
Antigens
Antibody Formation
Immunization
Self Tolerance
Clinical Trials
Therapeutics
Population

Keywords

  • IMMUNE THROMBOCYTOPENIC PURPURA
  • ADULT PATIENTS
  • REGULATORY CELLS
  • IN-VIVO
  • AUTOIMMUNE
  • ANTIGEN
  • AUTOANTIBODIES
  • EPITOPE
  • MODEL
  • TOLERANCE

ASJC Scopus subject areas

  • Hematology

Cite this

Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice. / Hall, Lindsay S; Lennon, Charlotte S; Hall, Andrew M; Urbaniak, Stanislaw J.; Vickers, Mark A; Barker, Robert N (Corresponding Author).

In: Haematologica, Vol. 104, No. 5, 05.2019, p. 1074-1082.

Research output: Contribution to journalArticle

Hall, Lindsay S ; Lennon, Charlotte S ; Hall, Andrew M ; Urbaniak, Stanislaw J. ; Vickers, Mark A ; Barker, Robert N. / Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice. In: Haematologica. 2019 ; Vol. 104, No. 5. pp. 1074-1082.
@article{9fe193f477e449598119aec311149d1e,
title = "Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice",
abstract = "Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. None of the individual peptides, delivered by a putative tolerogenic regimen, consistently suppressed the antibody response to subsequent immunization with human platelet glycoprotein IIb/IIIa. However, the combination of GPIIIa peptides aa6-20 and aa711-725, which contain the predominant helper epitopes in patients and elicited the strongest trends to suppress when used individually, did abrogate this response. The peptide combination also blunted, but did not reverse, the ongoing antibody response when given after immunization. Suppression of antibody was associated with reduced splenocyte T cell responsiveness to the antigen, and with the induction of a regulatory T cell population that is more responsive to the peptides than to purified platelet glycoprotein IIb/IIIa. Overall, these data demonstrate that combinations of peptides containing helper epitopes, such as platelet glycoprotein IIIa aa6-20 and aa711-725, can promote in vivo suppression of responses to the major antigen implicated in immune thrombocytopenia. The approach offers a promising therapeutic option to boost T cell regulation, which should be taken forward to clinical trials.",
keywords = "IMMUNE THROMBOCYTOPENIC PURPURA, ADULT PATIENTS, REGULATORY CELLS, IN-VIVO, AUTOIMMUNE, ANTIGEN, AUTOANTIBODIES, EPITOPE, MODEL, TOLERANCE",
author = "Hall, {Lindsay S} and Lennon, {Charlotte S} and Hall, {Andrew M} and Urbaniak, {Stanislaw J.} and Vickers, {Mark A} and Barker, {Robert N}",
note = "The study was funded by grants from the Medical Research Council (UK) Confidence in Concept, the Scottish National Blood Transfusion Service and the Wellcome Trust (UK).",
year = "2019",
month = "5",
doi = "10.3324/haematol.2017.179424",
language = "English",
volume = "104",
pages = "1074--1082",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "5",

}

TY - JOUR

T1 - Combination peptide immunotherapy suppresses antibody and helper T cell responses to the major human platelet autoantigen GPIIb/IIIa in HLA-transgenic mice

AU - Hall, Lindsay S

AU - Lennon, Charlotte S

AU - Hall, Andrew M

AU - Urbaniak, Stanislaw J.

AU - Vickers, Mark A

AU - Barker, Robert N

N1 - The study was funded by grants from the Medical Research Council (UK) Confidence in Concept, the Scottish National Blood Transfusion Service and the Wellcome Trust (UK).

PY - 2019/5

Y1 - 2019/5

N2 - Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. None of the individual peptides, delivered by a putative tolerogenic regimen, consistently suppressed the antibody response to subsequent immunization with human platelet glycoprotein IIb/IIIa. However, the combination of GPIIIa peptides aa6-20 and aa711-725, which contain the predominant helper epitopes in patients and elicited the strongest trends to suppress when used individually, did abrogate this response. The peptide combination also blunted, but did not reverse, the ongoing antibody response when given after immunization. Suppression of antibody was associated with reduced splenocyte T cell responsiveness to the antigen, and with the induction of a regulatory T cell population that is more responsive to the peptides than to purified platelet glycoprotein IIb/IIIa. Overall, these data demonstrate that combinations of peptides containing helper epitopes, such as platelet glycoprotein IIIa aa6-20 and aa711-725, can promote in vivo suppression of responses to the major antigen implicated in immune thrombocytopenia. The approach offers a promising therapeutic option to boost T cell regulation, which should be taken forward to clinical trials.

AB - Platelet destruction in immune thrombocytopenia is caused by autoreactive antibody and T cell responses, most commonly directed against platelet glycoprotein IIb/IIIa. Loss of self-tolerance in the disease is also associated with deficient activity of regulatory T cells. Having previously mapped seven major epitopes on platelet glycoprotein IIIa that are recognised by helper T cells from patients with immune thrombocytopenia, the aim was to test whether peptide therapy with any of these sequences, alone or in combination, could inhibit responses to the antigen in humanized mice expressing HLA-DR15. None of the individual peptides, delivered by a putative tolerogenic regimen, consistently suppressed the antibody response to subsequent immunization with human platelet glycoprotein IIb/IIIa. However, the combination of GPIIIa peptides aa6-20 and aa711-725, which contain the predominant helper epitopes in patients and elicited the strongest trends to suppress when used individually, did abrogate this response. The peptide combination also blunted, but did not reverse, the ongoing antibody response when given after immunization. Suppression of antibody was associated with reduced splenocyte T cell responsiveness to the antigen, and with the induction of a regulatory T cell population that is more responsive to the peptides than to purified platelet glycoprotein IIb/IIIa. Overall, these data demonstrate that combinations of peptides containing helper epitopes, such as platelet glycoprotein IIIa aa6-20 and aa711-725, can promote in vivo suppression of responses to the major antigen implicated in immune thrombocytopenia. The approach offers a promising therapeutic option to boost T cell regulation, which should be taken forward to clinical trials.

KW - IMMUNE THROMBOCYTOPENIC PURPURA

KW - ADULT PATIENTS

KW - REGULATORY CELLS

KW - IN-VIVO

KW - AUTOIMMUNE

KW - ANTIGEN

KW - AUTOANTIBODIES

KW - EPITOPE

KW - MODEL

KW - TOLERANCE

UR - http://www.mendeley.com/research/combination-peptide-immunotherapy-suppresses-antibody-helper-t-cell-responses-major-human-platelet-a

UR - http://www.scopus.com/inward/record.url?scp=85065467153&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.179424

DO - 10.3324/haematol.2017.179424

M3 - Article

VL - 104

SP - 1074

EP - 1082

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -